Sign in
WithdrawnNo phase

The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Key facts

Who runs it
Sadat City University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 Jan 2020
Ended
31 Dec 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Sildenafil Citrate
  • Placebo oral tablet
Record updated
14 July 2025
Why it stopped
Institutional and funding constrains

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960)
  • Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study

Who cannot take part

  • Patients with concurrent active medical condition
  • Patients with history of receiving Electroconvulsive therapy (ECT)
  • Patients with bipolar I or bipolar II disorder
  • Patients with personality disorders
  • Patients with eating disorders
  • Patients with history of seizures
  • Patients with inflammatory disorders
  • Patients with allergy or contraindications to the used medications
  • Cardiovascular disorders
  • Moderate or severe hepatic impairment
  • Severe renal impairment: creatinine clearance of ≤ 25 ml/min
  • Patients with substance dependence or abuse
  • Patients with finally pregnant or lactating females

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Antidepressant-like effects of sildenafil to its ability to modulate transduction pathways responsible for neuroplasticity. Treatment with sildenafil was shown to be PKG-dependent and lead to increased expression of cGMP, pCREB, BDNF and VGF in the hippocampus and prefrontal cortex (PFC), brain areas relevant to mood disorders pathophysiology. Sildenafil produces antidepressant-like effects by inhibiting oxidative stress in the hippocampus and by decreasing the levels of IL-1β in the hippocampus and striatum.

The 2 groups in the trial

  • Control groupPlacebo, for comparison

    Escitalopram 20 mg tablet plus one placebo tablet

    Treatment: Placebo oral tablet

  • Sildenafil groupTreatment being tested

    Escitalopram 20 mg tablet plus one Sildenafil 50 mg tablet

    Treatment: Sildenafil Citrate

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients: Randomized, Double-Blind, Placebo-Controlled Trial
Record updated
14 July 2025